Can J&J Get Its Diabetes Drug Past the Safety-First FDA?

The 10-5 vote by a Food and Drug Administration advisory committee recommending approval of Johnson & Johnson's diabetes drug canagliflozin sounds pretty decisive. But I wouldn't add the future revenue from the drug to your valuation just yet.

Canagliflozin, which will go by Invokana if it makes it to market, is a selective sodium glucose co-transporter 2 (SGLT-2) inhibitor. It's in the same class of drug as Bristol-Myers Squibb and AstraZeneca's dapagliflozin, which the FDA rejected last year over cancer concerns.

Invokana's problem has to do with a potential for increased cardiovascular risk. The advisory panel was asked about that issue specifically and only voted 8-7 that the drug isn't associated with an unacceptable cardiovascular risk.

After heart issues with GlaxoSmithKline's Avandia were discovered, the FDA required all drugmakers to run a cardiovascular study on diabetes drugs. If initial reports come out clean, the large study can be finished after the drug is on the market. But if there's a slight signal for cardiovascular risk, the company has to wait for the full data before approval.

With a pretty close vote on the cardiovascular risk, don't be shocked if the FDA errs on the side of caution, waiting until Johnson & Johnson produces the full data from its cardiovascular study due out in a few months.

Personally, I think the issue is probably nothing. The observed increase occurs in the first 30 days of taking the drug, which sounds more like a fluke observation than a serious problem. But there's no harm to the FDA to wait. It's not like this is a neglected area; there are plenty of drugs for diabetics to take until Johnson & Johnson can prove its drug is safe.

For Johnson & Johnson, the delay could cost the company billions since the patent clock keeps running through FDA reviews. Bristol-Myers and AstraZeneca, as well as Eli Lilly , which has a SGLT2 inhibitor that just posted positive phase 3 data, certainly wouldn't mind a delay, though.


The article Can J&J Get Its Diabetes Drug Past the Safety-First FDA? originally appeared on

Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.